Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces that it has appointed industry veteran Wolfgang Frisch as Vice President and Managing Director for Germany, effective 2 July.
Mainstay Medical has launched ReActiv8 in Germany, its first commercial market. Commercialization began in earnest over the last few months, following the Company’s fundraising that was completed in February 2018. Mr. Frisch will be instrumental in driving the commercial strategy forward, with a focus on adoption in a select number of high volume spine care centers to develop reference sites.
Mr. Frisch has over 30 years’ experience in the medical technology industry, including 20 years in leadership positions in sales, market access, market development, and general management positions, having spent a combined 15 years with Stryker and Medtronic. He most recently served on the executive board of Medtronic Germany, where he was also managing director for the strategic and tactical deployment of the sales organization in the entirety of Germany.
Jason Hannon, CEO of Mainstay, said: “I am delighted to announce that Wolfgang will be joining us as Managing Director for Germany. It is reflective of the clinical and market opportunity of ReActiv8 that we are able to attract a leader of Wolfgang’s caliber. Wolfgang will be instrumental in growing our commercial business in Germany, building clinical data around the commercial experience, and developing key reference sites throughout Germany who reflect their experience with ReActiv8 to the rest of the world.”
Mainstay is a medical device company focused on bringing to market an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands, and is listed on the regulated market of Euronext Paris (MSTY.PA) and the ESM of Euronext Dublin (MSTY.IE).
About Chronic Low Back Pain
One of the recognized root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilize the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.
People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilization put a significant burden on individuals, families, communities, industry and governments.
Further information can be found at www.mainstaymedical.com
CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.